Key points from article :
University College London (UCL) researchers developed a new immunotherapy called OPS-gamma-delta T, using engineered immune cells from healthy donors to target and kill bone cancer cells.
In mice with osteosarcoma, the most common bone cancer in teenagers, this therapy outperformed conventional immunotherapy, especially when combined with a bone-strengthening drug.
The treatment prevented tumor growth and kept the mice healthy for three months, offering a potential new therapy for osteosarcoma and other cancers that spread to the bone.
This promising research was published in the Science Translational Medicine journal.
